Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
an indication in prostate cancer outside the US or Japan after a Phase III trial failed to meet one of its primary endpoints. Ipsen's CONTACT-02 trial (NCT04446117), investigating Cabometyx in combination with Roche's Tecentriq (atezolizumab) in metastatic castration-resistant prostate cancer (mCRPC), did not meet statistical significance in overall survival (OS) improvement at 24 months, as per a 15 September press release. The French biopharma said that based on these results and the “challenging regulatory environment”, it would not be pursuing regulatory submissions for the combination therapy in mCRPC. Ipsen has commercialisation and development rights for the drug in countries outside the US and Japan following a 2016 deal with Cabometyx's original developer Exelixis. While Exelixis kept hold of US rights, it granted Japanese duties to Takeda in 2017. Ipsen has overseen approvals in renal cell carcinoma, thyroid carcinoma, and hepatocellular carcinoma indications for Cab
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberBusiness Wire
- Here is Why Growth Investors Should Buy Exelixis (EXEL) Now [Yahoo! Finance]Yahoo! Finance
- EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
- Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 10/29/24 - Beat
EXEL
Sec Filings
- 11/7/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- EXEL's page on the SEC website